HD-TAC7

• Description:

  HD-TAC7 is a potent PROTAC HDAC degrader with IC50 values of 3.6 μM, 4.2 μM and 1.1 μM for HDAC1, HDAC2 and HDAC3, respectively. HD-TAC7 can decreases NF-κB p65 in RAW 264.7 macrophages. HD-TAC7 can be used for the research of inflammatory diseases like asthma and chronic obstructive pulmonary disease (COPD) [1].

• UNSPSC:

  12352005

• Target:

  HDAC; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage; Epigenetics; PROTAC

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/hd-tac7.html

• Purity:

  98.75

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  NC1=CC(F)=CC=C1NC(C2=CC=C(C=C2)NC(CCCCNC(CNC3=C4C(N(C(C4=CC=C3)=O)C5CCC(NC5=O)=O)=O)=O)=O)=O

• Molecular Formula:

  C33H32FN7O7

• Molecular Weight:

  657.65

• References & Citations:

  [1]Fangyuan Cao, et al. Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC) . Eur J Med Chem. 2020 Dec 15;208:112800.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC1; HDAC2; HDAC3

• CAS Number:

  [2978763-95-8]